A Phase 1-2, Multicenter, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer

Registry ID

EUCTR2007-005961-36

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

Aegera Therapeutics Inc.

Start date

2008-03-27

Completion date

2008-08-22

Last update

2026-08-16

Conditions

• Advanced pancreatic adenocarcinoma

Summary

To determine the recommended dose of AEG35156 when used in combination with gemcitabine. To determine if AEG35156 can enhance the response rate of gemcitabine in patients with advanced pancreatic cancer.

Locations

• , , UK

Related clinical trials

• Sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma with KRAS p.G12C mutation

View on source registry